Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for KYOWA HAKKO KOGYO

All Data per March 2, 2023

Industry:

Drug Manufacturers—General

Last Close:

2,879.00 JPY

Expected Dividend:

1.67 %

Payoffs per Year:

2.0
Business Summary
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University; and an agreement with Amgen to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Competitors View

Ordering

ABBVIE

USA		 1.03 4.28%
3.61%		 7.39% 5.46% 1.0 4.36
-9.47%		 43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN		 0.96 2.56%
0.0%		 22.5% 6.68% 1.0 4.24
-32.13%		 32.9 15.38% 77.21 2.0

PFIZER

USA		 0.95 3.64%
3.96%		 2.76% 3.76% 1.0 3.02
-11.11%		 49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR		 1.04 4.07%
2.74%		 1.15% 3.92% 1.0 11.56
-3.86%		 98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN		 1.05 4.24%
0.0%		 0.0% 3.88% 1.0 8.15
-17.26%		 35.15 18.52% 61.0 5.0

SANOFI

FRA		 1.01 3.78%
4.03%		 0.74% 3.58% 1.0 0.57
-12.18%		 51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA		 0.98 2.8%
3.1%		 1.83% 2.78% 1.0 0.5
-24.44%		 34.92 17.8% 32.88 7.0

MERCK & CO.

USA		 1.12 3.12%
2.64%		 2.24% 3.15% 1.0 2.31
-11.68%		 55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN
 0.96 1.88%
1.67%		 7.74% 2.44% 1.0 3.6
-15.61%		 35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA		 1.16 2.74%
3.6%		 5.91% 3.26% 1.0 0.15
-42.43%		 33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA		 1.04 2.43%
1.22%		 2.86% 2.52% 1.0 7.52
-12.71%		 42.91 5.87% 18.4 11.0

ROCHE

CHE		 0.92 3.28%
3.51%		 0.79% 3.11% 1.0 1.4
-15.85%		 37.23 2.14% 26.53 12.0

AMGEN

USA		 1.0 2.42%
3.28%		 8.46% 3.24% 1.0 3.5
-9.93%		 35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR		 0.96 5.37%
5.27%		 0.35% 5.0% -0.5 0.21
-24.56%		 49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN		 0.96 2.43%
0.0%		 1.74% 2.4% 1.0 1.09
-19.06%		 27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN		 0.93 2.21%
2.54%		 0.0% 2.02% 1.0 -0.41
-14.62%		 28.52 12.2% 71.29 16.0

BAYER

GER		 1.02 2.51%
3.99%		 4.7% 2.83% 0.5 -0.36
-58.76%		 36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA		 0.98 2.68%
0.0%		 0.0% 2.46% 1.0 -1.0
13.03%		 44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP		 0.98 1.5%
nan%		 4.84% 1.7% -0.5 0.24
-46.29%		 31.86 -1.95% 31.7 nan

Information for KYOWA HAKKO KOGYO

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 849.00 20.00 2.36
2013 1,159.00 25.00 2.16
2014 1,136.00 25.00 2.20
2015 1,915.00 25.00 1.31
2016 1,616.00 25.00 1.55
2017 2,179.00 27.00 1.24
2018 2,077.00 35.00 1.69
2019 2,573.00 42.00 1.63
2020 2,814.00 66.00 2.35
2021 3,135.00 46.00 1.47
2023 2,879.00 48.08 1.67

Fundamentals

Chart